Log in
NYSE:AZN

AstraZeneca Stock Forecast, Price & News

$52.61
+0.01 (+0.02 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$51.44
Now: $52.61
$52.77
50-Day Range
$50.16
MA: $53.81
$58.02
52-Week Range
$36.15
Now: $52.61
$64.94
Volume14.78 million shs
Average Volume5.24 million shs
Market Capitalization$138.08 billion
P/E Ratio63.39
Dividend Yield1.67%
Beta0.5
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More
AstraZeneca logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 1.9Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-3749-5000
Employees70,600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.38 billion
Cash Flow$3.00 per share
Book Value$5.56 per share

Profitability

Net Income$1.34 billion

Miscellaneous

Outstanding Shares2,624,593,000
Market Cap$138.08 billion
Next Earnings DateN/A
OptionableOptionable
$52.61
+0.01 (+0.02 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AstraZeneca (NYSE:AZN) Frequently Asked Questions

How has AstraZeneca's stock been impacted by COVID-19 (Coronavirus)?

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AZN shares have increased by 18.0% and is now trading at $52.61.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AstraZeneca?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AstraZeneca?

Wall Street analysts have given AstraZeneca a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AstraZeneca wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NYSE:AZN) released its quarterly earnings data on Tuesday, November, 10th. The company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.03. The firm had revenue of $6.58 billion for the quarter, compared to analyst estimates of $6.65 billion. AstraZeneca had a return on equity of 37.72% and a net margin of 8.36%. The company's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.99 earnings per share.
View AstraZeneca's earnings history
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semi-annual dividend on Friday, July 31st. Stockholders of record on Friday, August 14th will be paid a dividend of $0.45 per share on Monday, September 14th. This represents a dividend yield of 2.5%. The ex-dividend date is Thursday, August 13th.
View AstraZeneca's dividend history
.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

What price target have analysts set for AZN?

11 Wall Street analysts have issued 1-year price objectives for AstraZeneca's stock. Their forecasts range from $60.00 to $65.00. On average, they expect AstraZeneca's stock price to reach $61.67 in the next year. This suggests a possible upside of 17.2% from the stock's current price.
View analysts' price targets for AstraZeneca
.

Are investors shorting AstraZeneca?

AstraZeneca saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 6,050,000 shares, an increase of 20.3% from the October 15th total of 5,030,000 shares. Based on an average daily volume of 4,320,000 shares, the days-to-cover ratio is currently 1.4 days.
View AstraZeneca's Short Interest
.

Who are some of AstraZeneca's key competitors?

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Moderna (MRNA), Tesla (TSLA), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD) and Walmart (WMT).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot D.V.M., M.B.A., CEO & Exec. Director (Age 61)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 68)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 49)
  • Prof. Ralph Knöll, Chief Scientist
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer
  • Ms. Fiona Cicconi, Exec. VP of HR
  • Dr. Menelas Pangalos, Exec. Vice-Pres of BioPharmaceuticals R&D
  • Dr. Ruud Dobber, Exec. Vice-Pres of BioPharmaceuticals Bus. Unit

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (1.18%), Fisher Asset Management LLC (0.66%), Arrowstreet Capital Limited Partnership (0.28%), BlackRock Inc. (0.26%), Winslow Capital Management LLC (0.22%) and Morgan Stanley (0.16%).
View institutional ownership trends for AstraZeneca
.

Which major investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Arrowstreet Capital Limited Partnership, Epoch Investment Partners Inc., BlackRock Inc., Nuveen Asset Management LLC, Galibier Capital Management Ltd., PFM Health Sciences LP, and Point72 Asset Management L.P..
View insider buying and selling activity for AstraZeneca
.

Which major investors are buying AstraZeneca stock?

AZN stock was purchased by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, BP PLC, Fisher Asset Management LLC, Lord Abbett & CO. LLC, Morgan Stanley, Acadian Asset Management LLC, OLD Mission Capital LLC, and Starr International Co. Inc..
View insider buying and selling activity for AstraZeneca
.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $52.61.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $138.08 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 70,600 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.